A research team led by Professor Chih-Yung Chiu at Linkou Chang Gung Memorial Hospital has developed a novel magnetic resonance spectroscopy (NMR)-based metabolite analysis method for assessing gut microbiome health and predicting asthma and allergy risk in young children. This non-invasive diagnostic approach provides a precise tool for early screening and prevention, offering a breakthrough in pediatric allergy management.
The increasing incidence of pediatric asthma and allergies poses significant challenges to children's quality of life and places a burden on families and healthcare systems. Conventional diagnostic methods, such as serum immunoglobulin E (IgE) testing, have limited accuracy and often rely on clinician experience, making widespread application difficult. Developing a more precise, accessible, and non-invasive diagnostic approach is essential for enhancing early intervention and treatment strategies.
To address these challenges, Professor Chiu's team leveraged nuclear magnetic resonance (NMR) spectroscopy to analyze metabolic profiles in pediatric fecal samples, specifically focusing on short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. SCFAs play a critical role in maintaining gut microbial balance and immune regulation. The study found that healthy children have SCFAs constituting approximately 60% of gut metabolites, whereas asthmatic children exhibit a significant reduction in butyrate levels, correlating with increased allergy risk. These findings suggest that monitoring SCFA variations could serve as a reliable biomarker for early asthma and allergy risk assessment.
To further refine diagnostic precision, the research team integrated machine learning algorithms into the metabolite analysis model, effectively distinguishing between healthy children and high-risk individuals. Compared to conventional IgE testing, this method demonstrated superior diagnostic performance, with an average accuracy of 84%, a sensitivity of 91%, and a specificity of 82%. Additionally, its non-invasive nature eliminates the need for blood sampling, reducing discomfort for young patients while improving acceptance among parents and healthcare providers.
Professor Chiu emphasized that NMR-based metabolite analysis not only serves as a valuable early detection tool for pediatric asthma and allergy risk but also lays the foundation for personalized health management. As precision medicine continues to advance, this technology has the potential to be extended to other chronic disease screenings, including gastrointestinal and metabolic disorders. Future integration with AI-driven data analytics platforms could further enhance diagnostic accuracy and enable tailored health recommendations.
Currently, the research team is actively conducting clinical trials to facilitate the widespread adoption of this innovative, non-invasive diagnostic technology, aiming to provide accurate, early allergy risk assessments and support effective pediatric asthma and allergy prevention strategies.
Resource:《新創動態》核磁共振光譜檢測代謝物 無創評估幼童過敏風險
